Still betting on Nvidia? Our AI picked this stock instead; it’s up 96%+ THIS MONTH
In a recent transaction reported to the Securities and Exchange Commission, Otis W. Brawley, a director at Lyell Immunopharma , Inc. (NASDAQ:LYEL), acquired a significant number of shares in the company. On March 31, Brawley purchased 35,640 shares of common stock at $0.56 per share, near the stock’s 52-week low of $0.48. This acquisition represents a total investment of $19,958. According to InvestingPro analysis, the company’s shares are currently undervalued, trading at just 0.38 times book value.
Following this transaction, Brawley holds a direct ownership of 35,640 shares in Lyell Immunopharma. The transaction underscores Brawley’s continued confidence in the company’s prospects, despite the stock’s 76% decline over the past year. Lyell Immunopharma, based in South San Francisco, is engaged in the pharmaceutical preparations industry, focusing on life sciences. The company maintains a strong financial position with a current ratio of 7.06, though InvestingPro analysis reveals 12 additional key factors affecting the company’s outlook.
In other recent news, Lyell Immunopharma announced the closure of its West Hills manufacturing facility, resulting in a reduction of approximately 73 jobs. This decision follows the transfer of technology to its Bothell, Washington facility, which is now prepared to support clinical trials and potential commercial launches. The closure is expected to incur costs between $3.0 million and $4.0 million, mainly due to severance and related expenses, recognized in the second and third quarters of 2025. H.C. Wainwright has maintained a Neutral rating on Lyell Immunopharma, with a price target of $1.00, as they monitor the progress of the company’s IMPT-314 drug candidate in ongoing trials. The analysts expressed interest in upcoming trial data while noting the competitive landscape and high efficacy benchmarks set by existing therapies. Additionally, Lyell Immunopharma faces a potential Nasdaq delisting due to non-compliance with the minimum bid price requirement, as its stock has closed below $1.00 for 33 consecutive business days. The company has until July 22, 2025, to meet the compliance criteria and is considering measures such as a reverse stock split to address the issue. Investors are closely observing these developments as the company navigates regulatory and market challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.